[<sup>68</sup>Ga]Ga-ABY-025 PET in HER2-positive breast cancer: Benefits and pitfalls in staging of axillary disease.
Ali Alhuseinalkhudhur(Uppsala University), Jens Benn Sørensen(University of Copenhagen), Joachim Feldwisch(Uppsala University), Henrik Lindman(Uppsala University), Mark Lubberink(Uppsala University), Nikolai C. Brun(Genmab (Denmark)), Irina Velikyan(Uppsala University), Per Liss(Uppsala University), Fredrik Y. Frejd(Uppsala University)
Cited by 1
Related Papers
Breast Cancer in Young Women: Poor Survival Despite Intensive Treatment
|PLoS ONE|2009|504
Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial
|The Lancet|2000|343
Measuring HER2-Receptor Expression In Metastatic Breast Cancer Using [<sup>68</sup>Ga]ABY-025 Affibody PET/CT
|Theranostics|2015|269
First-in-Human Molecular Imaging of HER2 Expression in Breast Cancer Metastases Using the <sup>111</sup>In-ABY-025 Affibody Molecule
|Journal of Nuclear Medicine|2014|260
In Vivo Visualization of Amyloid Deposits in the Heart with <sup>11</sup>C-PIB and PET
|Journal of Nuclear Medicine|2012|258